Halozyme director Matthew L. Posard sells $569,752 in common shares
HALO•Halozyme Therapeutics director Matthew L. Posard sold 5,230 common shares on Oct. 1, 2026, for prices ranging from $107.168 to $110.04 per share. His directly owned stake fell to 53,609 shares.
1. Share sale details
Posard sold 5,230 Halozyme common shares on Oct. 1, 2026. The sales prices ranged from $107.168 to $110.04 per share, and his directly owned stake fell to 53,609 shares.
